REGULATION OF NEWBORN GENOMIC SEQUENCING PROGRAMS

1. INTRODUCTION

Newborn genomic sequencing involves analysing a newborn's DNA to identify genetic disorders, disease susceptibility, and potentially actionable medical conditions. It may support early diagnosis and treatment, particularly for rare inherited diseases. However, population-wide sequencing can also reveal incidental findings, carrier status, familial information, and risks of future disease.

Regulation must balance public health benefits with parental consent, the child's best interests, privacy, confidentiality, and the child's future autonomy. India does not have a single comprehensive statute specifically governing all newborn genomic sequencing programs. Their regulation depends on applicable medical, data-protection, research-ethics, and genetic-testing requirements.

2. LEGAL FRAMEWORK IN INDIA

A. CONSTITUTIONAL PROTECTION

Article 21 of the Constitution protects life and personal liberty, including privacy and bodily autonomy. Article 14 requires lawful and non-arbitrary State action. Government-sponsored sequencing programs must therefore have an appropriate legal basis and safeguards proportionate to their objectives.

B. CLINICAL AND RESEARCH REQUIREMENTS

The New Drugs and Clinical Trials Rules, 2019, may apply where sequencing forms part of a regulated clinical trial. The Indian Council of Medical Research's National Ethical Guidelines for Biomedical and Health Research Involving Human Participants provide important guidance on genetic research, consent, confidentiality, and biological-sample management.

Research involving newborns requires parental or legally authorised representative consent, appropriate ethics review, and protection of the child's welfare. Clinical diagnostic testing and research sequencing must be distinguished because permission for treatment-related testing does not automatically authorise secondary research.

C. DATA PROTECTION

The Digital Personal Data Protection Act, 2023, and applicable rules and commencement provisions must be considered when identifiable genomic information is processed digitally. Organisations should establish lawful processing arrangements, appropriate security safeguards, restricted access, and transparent retention policies.

D. PRENATAL DIAGNOSTIC REGULATION

The Pre-Conception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994, regulates specified prenatal diagnostic activities and prohibits sex selection. Its application depends on the procedure and circumstances. It should not be treated as a general statutory framework for sequencing performed after birth.

3. PRINCIPAL REGULATORY REQUIREMENTS

A. PARENTAL CONSENT: Parents should receive understandable information about the test's purpose, limitations, potential findings, and consequences. Where consent is legally required, it must be voluntary and appropriately documented.

B. CLINICAL VALIDITY: Programs should use validated testing methods, qualified professionals, confirmatory testing where appropriate, and clinically meaningful interpretation.

C. RETURN OF RESULTS: Policies should distinguish actionable childhood conditions from adult-onset conditions and incidental findings. Genetic counselling should be available where appropriate.

D. PRIVACY AND STORAGE: Programs should restrict access, define retention periods, secure samples and sequence data, and establish rules for secondary research and sharing.

E. EQUITY AND FOLLOW-UP: Screening is beneficial only when reliable diagnostic confirmation, treatment, counselling, and follow-up services are accessible.

4. RELEVANT CASE LAWS

1. JUSTICE K.S. PUTTASWAMY (RETD.) v. UNION OF INDIA (2017) — DIRECT CONSTITUTIONAL PRIVACY AUTHORITY

The Supreme Court recognised privacy as a fundamental right, including informational privacy.

Application: Newborn sequencing programs must justify the collection, storage, and disclosure of identifiable genomic information and implement safeguards against unnecessary or disproportionate processing.

2. SAMIRA KOHLI v. DR. PRABHA MANCHANDA (2008) — DIRECT CONSENT PRINCIPLE

The Supreme Court explained the requirements of valid informed consent in medical treatment.

Application: Parents should receive adequate information before consenting on behalf of a newborn. The judgment supports meaningful disclosure but does not specifically determine the rules governing genomic screening.

3. GOUTAM KUNDU v. STATE OF WEST BENGAL (1993) — ANALOGOUS DNA-TESTING AUTHORITY

The Supreme Court held that blood tests to determine paternity should not be ordered routinely and discussed the circumstances in which such testing may be justified.

Application: The case supports caution regarding intrusive genetic testing. However, paternity testing differs materially from clinically justified newborn screening, so the judgment does not prohibit medically necessary genomic testing.

4. R. RAJENDRAN v. KAMAR NISHA (2025) — ANALOGOUS DNA-PRIVACY AUTHORITY

The Supreme Court emphasised privacy, dignity, and proportionality in considering compelled DNA testing involving a child and family relationships.

Application: The decision reinforces the need to justify intrusive genetic procedures and protect children's interests. It concerns DNA testing in a legal dispute, not a population-based newborn screening program.

5. SUCHITA SRIVASTAVA v. CHANDIGARH ADMINISTRATION (2009) — ANALOGOUS AUTONOMY AUTHORITY

The Supreme Court recognised reproductive autonomy as an aspect of personal liberty under Article 21.

Application: Although the case concerns reproductive decision-making rather than newborn genetics, its autonomy principles help explain why decisions affecting bodily integrity and personal information require careful legal and ethical consideration.

6. DOE v. ADAMS, INDIANA COURT OF APPEALS (2016) — DIRECTLY RELEVANT COMPARATIVE AUTHORITY

The court considered a challenge concerning the retention of a child's newborn dried-blood-spot sample without permission.

Application: The case illustrates the legal and privacy concerns that may arise when samples collected for newborn screening are retained or used for additional purposes. It is persuasive comparative authority only and is not binding in India.

5. PRACTICAL COMPLIANCE MEASURES

Programs should adopt clear consent forms, clinical eligibility criteria, confirmatory testing protocols, genetic counselling procedures, and policies governing incidental findings. Research use should be separately assessed, with independent ethics review and appropriate consent.

Identifiable genomic data should be protected through access controls, encryption, secure storage, and documented sharing arrangements. Parents should be informed about retention and future use, while program designers should consider the child's evolving autonomy and avoid unnecessary disclosure of adult-onset risks when no childhood intervention is available.

6. CONCLUSION

Newborn genomic sequencing can improve early diagnosis and treatment, but it creates enduring questions concerning consent, privacy, familial information, and future autonomy. India's constitutional protections, applicable data-protection legislation, clinical requirements, and ICMR ethical guidance provide important safeguards, although no single statute comprehensively regulates every aspect of newborn genomic sequencing.

The cited judgments establish relevant principles concerning privacy, consent, autonomy, and DNA testing. None directly establishes a complete legal framework for newborn genomic sequencing programs. Responsible implementation therefore requires proportionate testing, meaningful parental consent where required, clinically justified reporting, secure data management, and continuing protection of the child's interests.